OBJECTIVE: To compare the effects of tibolone and continuous combined hormone therapy on circulating sex steroids and their binding proteins and their relationship to mammographic density. STUDY DESIGN: A prospective, double-blind placebo-controlled study. A total of 166 postmenopausal women were equally randomized to receive tibolone 2.5 mg, estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA) or placebo. Serum analyses of sex steroids, insulin-like growth factor (IGF-I) and binding proteins and assessment of mammographic breast density were performed at baseline and after 6 months of treatment. RESULTS: Estrogens were markedly increased and androgens decreased by E2/NETA. In contrast, tibolone had only a minor influence on circulating estrogens. Sex hormone binding globulin (SHBG) levels were reduced by 50%, while levels of androgens increased. Baseline values of estrone sulfate (E1S), around 1.0-1.1 nmol/l, were increased to 44.7 nmol/l by E2/NETA and to only 1.7 nmol/l by tibolone (p < 0.001). Mammographic breast density displayed a negative correlation with age and body mass index and a positive association with SHBG. After 6 months there was also a negative correlation with levels of free testosterone. Conclusion We found that tibolone and E2/NETA caused distinct differences in estrogen/androgen status and blood levels of possible breast mitogens. The negative association between free testosterone and mammographic density could be a possible explanation for tibolone having less influence on the breast.
RCT Entities:
OBJECTIVE: To compare the effects of tibolone and continuous combined hormone therapy on circulating sex steroids and their binding proteins and their relationship to mammographic density. STUDY DESIGN: A prospective, double-blind placebo-controlled study. A total of 166 postmenopausal women were equally randomized to receive tibolone 2.5 mg, estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA) or placebo. Serum analyses of sex steroids, insulin-like growth factor (IGF-I) and binding proteins and assessment of mammographic breast density were performed at baseline and after 6 months of treatment. RESULTS: Estrogens were markedly increased and androgens decreased by E2/NETA. In contrast, tibolone had only a minor influence on circulating estrogens. Sex hormone binding globulin (SHBG) levels were reduced by 50%, while levels of androgens increased. Baseline values of estrone sulfate (E1S), around 1.0-1.1 nmol/l, were increased to 44.7 nmol/l by E2/NETA and to only 1.7 nmol/l by tibolone (p < 0.001). Mammographic breast density displayed a negative correlation with age and body mass index and a positive association with SHBG. After 6 months there was also a negative correlation with levels of free testosterone. Conclusion We found that tibolone and E2/NETA caused distinct differences in estrogen/androgen status and blood levels of possible breast mitogens. The negative association between free testosterone and mammographic density could be a possible explanation for tibolone having less influence on the breast.
Authors: Carolyn J Crandall; Aaron K Aragaki; Jane A Cauley; Anne McTiernan; Joann E Manson; Garnet L Anderson; Jean Wactawski-Wende; Rowan T Chlebowski Journal: Breast Cancer Res Treat Date: 2011-10-07 Impact factor: 4.872
Authors: Carolyn J Crandall; Min Guan; Gail A Laughlin; Giske A Ursin; Frank Z Stanczyk; Sue A Ingles; Elizabeth Barrett-Connor; Gail A Greendale Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: Rodolfo Pinto-Almazán; Julia J Segura-Uribe; Eunice D Farfán-García; Christian Guerra-Araiza Journal: Biomed Res Int Date: 2017-01-16 Impact factor: 3.411
Authors: Carolyn J Crandall; Mary E Sehl; Sybil L Crawford; Ellen B Gold; Laurel A Habel; Lesley M Butler; Maryfran R Sowers; Gail A Greendale; Janet S Sinsheimer Journal: Breast Cancer Res Date: 2009-07-27 Impact factor: 6.466